Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, 7-ADCA, 7-ACA, D-7ACA, and penicillin industrial potassium; pharmaceutical intermediates, anti-infective pharmaceutical intermediates salt, and ceftriaxone sodium crude salt; and amoxicillin, clavulanic acid series, azithromycin, and ceftriaxone sodium. It also provides anti-infective pharmaceutical raw materials; urogenital system pharmaceutical raw materials, systemic anti-infective drugs; cardiovascular system medications; urogenital system medications and hormones; drugs for the nervous system; diclofenac sodium sustained-release tablets for musculoskeletal system; digestive tract and metabolism medications; anti-tumor and immunomodulatory agent; blood and hematopoietic system medications; respiratory system medications; animal vaccines; and general health products. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 2000 and is based in Shanghai, China.
Metrics to compare | 600420 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600420PeersSector | |
---|---|---|---|---|
P/E Ratio | 14.8x | 30.5x | −0.5x | |
PEG Ratio | −5.55 | −0.16 | 0.00 | |
Price/Book | 1.1x | 3.2x | 2.6x | |
Price / LTM Sales | 1.6x | 4.8x | 3.3x | |
Upside (Analyst Target) | 71.5% | 15.8% | 42.9% | |
Fair Value Upside | Unlock | 1.5% | 6.2% | Unlock |